News
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) ...
Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an aggressive type of blood cancer, according to a new study from scientists at ...
17h
SurvivorNet on MSNNew Hope for Patients With Advanced Lung Cancer: Datroway, A New FDA ApprovalA new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...
On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...
With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.
1d
GlobalData on MSNPiramal Pharma announces $90m investment to expand US sites"Piramal Pharma announces $90m investment to expand US sites" was originally created and published by Pharmaceutical ...
Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...
Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.
ACROBiosystems has developed a series of specialized proteases for the screening and validation of ADC linkers, focusing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results